ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,185.87
0.10%
US Tech 100
17,614.40
0.02%
Dow Jones
38,880.73
0.07%
Brent Oil
83.125
-0.42%
Bitcoin
63,130.06
-0.06%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Personalis Inc (PSNL) Quote

Personalis Inc

Personalis Inc (PSNL)

Persimmon PLC
Persimmon PLC
Persimmon PLC
1.635
0.045
( 2.83% )
Updated: 15:08:37
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
1.635
Bid
1.63
Ask
1.64
Volume
160,253
1.56 Day's Range 1.73
0.8906 52 Week Range 2.60
Market Cap
82.321M
Previous Close
1.59
Open
1.58
Last Trade
5
@
1.64
Last Trade Time
15:10:32
Financial Volume
$ 265,300
VWAP
1.6555
Average Volume (3m)
313,767
Shares Outstanding
50,503,889
Dividend Yield
-
PE Ratio
-0.76
Earnings Per Share (EPS)
-2.14
Revenue
73.48M
Net Profit
-108.3M

About Personalis Inc

Personalis Inc is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT... Personalis Inc is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions. Show more

Sector
Medical Laboratories
Industry
Medical Laboratories
Website
www.personalis.com
Headquarters
Dover, Delaware, USA
Founded
1970
Personalis Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker PSNL. The last closing price for Personalis was $1.59. Over the last year, Personalis shares have traded in a share price range of $ 0.8906 to $ 2.60.

Personalis currently has 50,503,889 shares outstanding. The market capitalization of Personalis is $82.32 million. Personalis has a price to earnings ratio (PE ratio) of -0.76.

PSNL Latest News

More News

Personalis to Announce First Quarter 2024 Financial Results

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2024 financial results on Wednesday, May 8, 2024. In conjunction...

April 24 2024
Business Wire

Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on...

March 28 2024
Business Wire

Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts featuring data for the company’s NeXT Personal®...

March 28 2024
Business Wire

Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring

Blood-based assay uses personalized tumor-informed approach designed to detect cancer recurrence early with an ultra-sensitive approach Personalis, Inc. (Nasdaq: PSNL), a leader in advanced...

March 26 2024
Business Wire

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on November 15, 2023 and...

March 19 2024
Business Wire

Personalis Reports Fourth Quarter and Full Year 2023 Financial Results

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided...

February 28 2024
Business Wire

Form 8-K - Current report

February 28 2024
Edgar (US Regulatory)

Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, February 28...

February 14 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

January 31 2024
Edgar (US Regulatory)

Personalis to Participate at Upcoming Investor Conferences

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the following investor conferences: BTIG MedTech, Digital...

January 31 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.26519.34306569341.371.851.343083071.55048646CS
40.18512.75862068971.451.851.182334051.37202472CS
120.347226.96070818451.28781.851.153137671.47695598CS
260.56552.80373831781.072.380.89065187371.47993488CS
52-0.625-27.65486725662.262.60.89063636051.56320665CS
156-20.435-92.591753511622.0728.470.89064378317.34563242CS
260-22.065-93.101265822823.753.460.890649018014.69687486CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GSUNGolden Sun Health Technology Group Ltd
$ 5.01
(72.76%)
42.98M
NUWENewellis Inc
$ 0.262564
(53.55%)
128.76M
NUZENuZee Inc
$ 1.94
(45.86%)
25.79M
PEGYPineapple Energy Inc
$ 0.0769
(44.55%)
297.96M
RNAZTransCode Therapeutics Inc
$ 1.16
(42.38%)
3.54M
NUVOHoldco Nuvo Group DG Ltd
$ 2.94
(-44.00%)
1.61M
RGFReal Good Food Company Inc
$ 0.53
(-32.82%)
1.89M
SHOTWSafety Shot Inc
$ 0.30
(-28.57%)
4.98k
AGRIAgriFORCE Growing Systems Ltd
$ 0.1036
(-28.25%)
3.73M
STIMNeuronetics Inc
$ 2.72
(-27.47%)
835.09k
PEGYPineapple Energy Inc
$ 0.0769
(44.55%)
297.96M
FFIEFaraday Future Intelligent Electric Inc
$ 0.0439
(6.30%)
165.58M
NKLANikola Corporation
$ 0.596225
(-6.46%)
142.52M
NUWENewellis Inc
$ 0.262564
(53.55%)
128.76M
SQQQProShares UltraPro Short QQQ
$ 10.71
(0.09%)
84.73M

PSNL Discussion

View Posts
glenn1919 glenn1919 3 days ago
PSNL............................https://stockcharts.com/h-sc/ui?s=PSNL&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 months ago
PSNL..................................https://stockcharts.com/h-sc/ui?s=PSNL&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 7 months ago
PSNL new 52=week low
👍️0
ottoman ottoman 7 months ago
Damn, is Cathy dumping? This turd sandwich never taste any better the more I nibble.
👍️0
Monksdream Monksdream 7 months ago
PSNL new 52 week low
👍️0
Invest-in-America Invest-in-America 1 year ago
PSNL: Got some nice REVS/INCOME news late yesterday, Peeps --- could get a little run-up today.
https://pulse2.com/why-the-personalis-stock-increased-over-10-psnl/
👍️0
Timetravelerdos Timetravelerdos 3 years ago
Personalis Announces Delivery of the 100,000th Genome to the U.S. Department of Veterans Affairs Million Veteran Program


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, announced today that it has delivered the 100,000th whole human genome sequence dataset to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). Although Personalis has been contracted by the VA MVP since 2012, the program has accelerated and over 50,000 of these genomes have been delivered in 2020.

"The VA MVP is the largest whole genome sequencing project in the United States and this is a significant milestone for both the program and for Personalis," said John West, Chief Executive Officer. "Population-scale sequencing projects of this nature represent a cornerstone in our effort to accelerate the advancement of precision medicine across a wide range of disease areas. With our sizable investments in the technology and infrastructure, necessary to win and execute these projects, Personalis sees population genomics and health as key priorities for our company. We congratulate the VA MVP for their visionary leadership and note that VA scientists now list over 50 peer reviewed publications from the Program."

https://finance.yahoo.com/news/personalis-announces-delivery-100-000th-210700535.html
👍️0
JGrumby JGrumby 5 years ago
Hearing that Monday PSNL will start to get Wall street research reports. Look at PSNL vs GH and NVTA etc
👍️0
JGrumby JGrumby 5 years ago
Nice day after the post IPO sell off.
👍️0

Your Recent History

NASDAQ
PSNL
Personalis
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved